Ipsen (OTCMKTS:IPSEY) Stock Rating Upgraded by Royal Bank of Canada
Royal Bank of Canada upgraded shares of Ipsen (OTCMKTS:IPSEY – Free Report) from a hold rating to a moderate buy rating in a research report released on Monday, Zacks.com reports. Ipsen Stock Up 3.8 % Shares of IPSEY stock opened at $31.77 on Monday. Ipsen has a 52-week low of $26.97 and a 52-week high […]
Sandoz Group (OTCMKTS:SDZNY) Stock Rating Lowered by Royal Bank of Canada
Royal Bank of Canada lowered shares of Sandoz Group (OTCMKTS:SDZNY – Free Report) from a moderate buy rating to a hold rating in a research note released on Monday morning, Zacks.com reports. Sandoz Group Price Performance Sandoz Group stock opened at $40.78 on Monday. The firm’s 50-day moving average is $41.75 and its 200-day moving […]
Royal Bank of Canada Lowers Sandoz Group (OTCMKTS:SDZNY) to Hold
Royal Bank of Canada downgraded shares of Sandoz Group (OTCMKTS:SDZNY – Free Report) from a moderate buy rating to a hold rating in a research report report published on Monday, Zacks.com reports. Sandoz Group Trading Down 0.4 % Shares of SDZNY opened at $40.78 on Monday. Sandoz Group has a 12-month low of $25.71 and […]
Ipsen (OTCMKTS:IPSEY) Rating Increased to Moderate Buy at Royal Bank of Canada
Royal Bank of Canada upgraded shares of Ipsen (OTCMKTS:IPSEY – Free Report) from a hold rating to a moderate buy rating in a research note issued to investors on Monday morning, Zacks.com reports. Ipsen Price Performance Shares of OTCMKTS IPSEY opened at $31.77 on Monday. The company’s fifty day moving average price is $29.36 and […]
VBI Vaccines (NASDAQ:VBIV) Research Coverage Started at StockNews.com
StockNews.com began coverage on shares of VBI Vaccines (NASDAQ:VBIV – Free Report) in a report released on Tuesday. The firm issued a sell rating on the biopharmaceutical company’s stock. VBI Vaccines Stock Performance VBI Vaccines has a 1 year low of $0.06 and a 1 year high of $1.35. The company has a 50 day […]
Cellectar Biosciences (NASDAQ:CLRB) Upgraded at StockNews.com
StockNews.com upgraded shares of Cellectar Biosciences (NASDAQ:CLRB – Free Report) to a sell rating in a research report sent to investors on Tuesday. Cellectar Biosciences Stock Performance Cellectar Biosciences stock opened at $2.11 on Tuesday. The firm has a market capitalization of $75.64 million, a P/E ratio of -0.69 and a beta of 0.99. The […]
Evelo Biosciences Target of Unusually Large Options Trading (NASDAQ:EVLO)
Evelo Biosciences, Inc. (NASDAQ:EVLO – Get Free Report) was the target of unusually large options trading on Wednesday. Stock traders acquired 1,885 put options on the stock. This represents an increase of approximately 1,101% compared to the typical volume of 157 put options. Evelo Biosciences Stock Performance The company has a market cap of $2,000.00, […]
StockNews.com Initiates Coverage on Nabriva Therapeutics (NASDAQ:NBRV)
StockNews.com assumed coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Free Report) in a research note released on Monday. The firm issued a hold rating on the biotechnology company’s stock. Nabriva Therapeutics Price Performance The firm has a market capitalization of $45.46 million, a P/E ratio of -0.07 and a beta of 1.53. Nabriva Therapeutics […]
Firsthand Technology Value Fund (NASDAQ:SVVC) Research Coverage Started at StockNews.com
StockNews.com began coverage on shares of Firsthand Technology Value Fund (NASDAQ:SVVC – Free Report) in a research note issued to investors on Sunday. The brokerage issued a hold rating on the investment management company’s stock. Firsthand Technology Value Fund Price Performance Shares of SVVC opened at $0.07 on Friday. The company has a market capitalization […]
Genocea Biosciences (NASDAQ:GNCA) Coverage Initiated by Analysts at StockNews.com
StockNews.com initiated coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Free Report) in a report issued on Sunday morning. The brokerage issued a sell rating on the biotechnology company’s stock. Genocea Biosciences Price Performance The firm has a market cap of $6,000.00, a P/E ratio of 0.00 and a beta of 1.61. Genocea Biosciences has […]
Nabriva Therapeutics (NASDAQ:NBRV) Earns Hold Rating from Analysts at StockNews.com
StockNews.com initiated coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Free Report) in a research report released on Monday. The firm issued a hold rating on the biotechnology company’s stock. Nabriva Therapeutics Price Performance The company has a current ratio of 0.85, a quick ratio of 0.52 and a debt-to-equity ratio of 0.12. Nabriva Therapeutics […]
last updated on 20 Sep 16:36